Case report

Juneyoug Koh, MD1, Eui-seok Jung, MD1, Se Jin Jang, MD2, Dong Kwan Kim, MD3, Byong Sop Lee, MD1, Ki-Soo Kim, MD1, Ellen Ai-Rhan Kim, MD1
Departments of 1Pediatrics, 2Pathology, and 3Thoracic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Congenital pulmonary airway malformation (CPAM), formerly known as congenital cystic adenomatoid malformation, is a rare developmental lung abnormality, occurring in 1 per 8,300–35,000 live births, characterized by polycystic lesions in the terminal bronchioles.1) In more than half of diagnosed patients, it is asymptomatic and incidentally discovered through chest radiography in adulthood. Only 25% of patients with CPAM exhibit clinical symptoms at birth.2,3) In symptomatic cases, normal lung tissue is replaced by polycystic lesions, leading to cyanosis and dyspnea, pneumothorax, hemothorax, and infections. In addition, multiple reports have indicated associations between CPAM and malignant neoplasms, such as rhabdomyosarcoma, pleuropulmonary blastoma, bronchioloalveolar carcinoma, and mucinous adenocarcinoma.4)

Stocker et al.5 categorized CPAM into 5 subtypes according to gross appearance and histological characteristics. Among the five subtypes, type I is predominant, and has been associated with malignancy.4) The present case is the first report of mucinous adenocarcinoma in a Korean neonate with type II CPAM.

Key words: Congenital cystic adenomatoid malformation of lung, Mucinous adenocarcinoma, Newborn Infant

Introduction

Congenital pulmonary airway malformation (CPAM), formerly known as congenital cystic adenomatoid malformation, is a rare developmental lung abnormality, occurring in 1 per 8,300–35,000 live births, characterized by polycystic lesions in the terminal bronchioles.1) In more than half of diagnosed patients, it is asymptomatic and incidentally discovered through chest radiography in adulthood. Only 25% of patients with CPAM exhibit clinical symptoms at birth.2,3) In symptomatic cases, normal lung tissue is replaced by polycystic lesions, leading to cyanosis and dyspnea, pneumothorax, hemothorax, and infections. In addition, multiple reports have indicated associations between CPAM and malignant neoplasms, such as rhabdomyosarcoma, pleuropulmonary blastoma, bronchioloalveolar carcinoma, and mucinous adenocarcinoma.4)

Stocker et al.5 categorized CPAM into 5 subtypes according to gross appearance and histological characteristics. Among the five subtypes, type I is predominant, and has been associated with malignancy.4) The present case is the first report of mucinous adenocarcinoma in a Korean neonate with type II CPAM.
Case report

A male neonate weighing 3,080 g was born at 39\textsuperscript{+2} weeks gestational age (GA) via normal vaginal delivery, with Apgar scores of 9 at 1 and 5 minutes of age. Prenatal ultrasonography at GA 22\textsuperscript{+0} weeks confirmed a polycystic lung lesion measuring 48×60×39 mm and occupying the entire left lower lung lobe, accompanied by a mediastinal shift and diaphragm inversion. Confirmation of progressive scalp edema, ascites, and pleural effusion led to a thoracoamniotic shunt operation. Obstetric ultrasonography at GA 23\textsuperscript{+4} weeks indicated partial improvement of hydrops fetalis, with no change in the cystic left lung lesion.

Continuously low (60\%-70\%) oxygen saturation levels, even with administration of 100\% oxygen at 5 L/m, necessitated endotracheal intubation of the neonate in the delivery room, followed by ventilator support in the neonatal intensive care unit. We performed chest computed tomography at 9 days of age (Fig. 1).

Left lower lobectomy was performed at 10 days of age to remove the aforementioned lesions. At the time of surgery, the left lower lobe was enlarged by the cystic malformation, and the left upper lobe was relatively small. Inspection of the resected lobe revealed polycystic lesions, ranging in diameter from 8 to 20 mm, with the main cyst measuring 35×20 mm. Biopsy revealed normal respiratory epithelial cells coexisting with cells undergoing malignant transformation. These were later confirmed to be mucinous adenocarcinoma (Fig. 2).

The KRAS sequence analysis revealed a somatic mutation in codon 12 (GGT \rightarrow GAT), suggesting development of a mucinous adenocarcinoma in the background of mucinous metaplasia (Fig. 3).

There were no other abnormal findings, aside from the respiratory disorder. The patient was discharged at 32 days postoperatively, and is currently doing well at age 2.4 years.

Discussion

CPAM characteristically presents as a multicystic mass of pulmonary tissue with proliferation of bronchial structures at the expense of alveoli. The specific cause of CPAM is unknown; it is presently considered a hamartomatous malformation or a localized developmental arrest.\textsuperscript{1,3} The clinical symptoms of CPAM are diverse.

![Fig. 1.](image1.png)
(A) Several large cysts are aggregated on the left lower lobe, with the largest cyst measuring 6 cm in diameter. The left upper lobe has normal features, but is displaced towards the upper section with a decrease in volume due to the mass effect. (B) The mediastinal structures indicate signs of right-sided midline shifting caused by the malformation of the left lower lobe, whereas the right lung has diminished in volume, especially the right upper lobe.

![Fig. 2.](image2.png)
(A) Inspection of the resected lobe revealed polycystic lesions, ranging in diameter from 8 to 20 mm, with the main cyst measuring 35×20 mm. (B) Analysis of pathology revealed type II congenital pulmonary airway malformation with extensive mucinous metaplasia. (H&E, ×40)
Lung adenocarcinoma associated with congenital pulmonary airway malformation

CPAM is asymptomatic in more than half of affected patients and the disease is incidentally discovered on chest radiography, while 25% exhibit clinical symptoms at birth.1,3 Ruchonnet-Metrailler et al.3 reported that 25% of CPAM patients exhibited respiratory symptoms, with 13% requiring inhaled oxygen, and 11% requiring mechanical ventilation. Symptoms may arise as a consequence of lung immaturity caused by the cystic malformation, with a mediastinal shift, inverted diaphragm, spontaneous pneumothorax, pleural effusion, hemothorax, repetitive mass infections, and hydrops fetalis during the fetal period, due to the pressure effect on the inferior vena cava. Furthermore, associations with malignant neoplasms such as rhabdomyosarcoma, pleuropulmonary blastoma, and adenocarcinoma have been reported. The diagnosis of adenocarcinoma in this pediatric patient was largely decided by KRAS mutation.

< K-RAS >

Fig. 3. Presence of a mutation in codon 12 of KRAS: G12D (GGT→GAT).

Table 1. Summarized clinical presentation of cases of MAC arising in CPAM in children reported before 2016

| Study          | N*  | Age   | Sex | Pre-Dx† | Symptoms                                      | Loc‡ | Surgical procedure                          | Dx§   | Lung tumor |
|---------------|-----|-------|-----|---------|-----------------------------------------------|------|---------------------------------------------|-------|-----------|
| Ohye, 199816  | 1   | 6 yr  | M   | No      | Pneumonia, intermittent cough, and chest pain | LLL  | LLL segmentectomy + right middle lobectomy later | CPAM 1 | BAC       |
| Granata, 199817 | 1  | 11 yr | M   | No      | Recurrent pneumonia                            | LLL  | Left lower lobectomy                        | CPAM 1 | BAC       |
| Papagiannopoulos, 200218 | 2  | NR    | NR  | NR      | NR                                            | NR   | NR                                          | CPAM 1 | BAC       |
| MacSweeney, 200319 | 2  | 6 mo  | M   | No      | NR                                            | RLL  | Right lower lobectomy                       | CPAM 1 | BAC       |
| Stacher, 200418 | 4  | 3 yr  | M   | NR      | NR                                            | NR   | Left lower lobectomy                        | CPAM 1 | BAC       |
| Newborn       |     |       |     |         |                                               |      |                                              |       |           |
| Loachimescu, 200520 | 1  | 6 yr  | M   | No      | Recurrent fever, chest pain, and cough         | LLL  | Left lower lobectomy                        | CPAM 1 | BAC, AC  |
| Ramos, 200721  | 1   | 8 yr  | F   | No      | Dry cough since age 2, recurrent broncho-pneumonia | LLL  | Left lower lobectomy                        | CPAM 1 | BAC       |
| Abecasis, 200821 | 1  | 14 yr | M   | No      | Asymptomatic                                   | RLL  | Right lower lobectomy                       | CPAM 1 detected 1 yr earlier | BAC     |
| Summers, 201022  | 1  | 8 yr  | F   | No      | Asthma since age 2, left chest pain since age 6 | LLL  | Left lower lobectomy                        | CPAM 1 | BAC       |
| Giubergia, 201223 | 1  | Newborn | F  | No      | Acute respiratory distress                     | Right lung | Right pneumonectomy                         | CPAM 1 | BAC       |
| Ishida, 201324  | 1   | 9 yr  | F   | No      | Fever and lung abscess, Previous lung abscess at age 6 | RLL  | Right lower lobectomy                        | CPAM 1 | BAC       |
| Li, 201425      | 1   | 2 day | M   | No      | Respiratory distress                           | RLL  | Right lower lobectomy                        | CPAM 1 and 2 | BAC     |
| Balkanli, 201426 | 1  | Newborn | F  | Yes     | Respiratory distress                           | LUL  | Left upper lobectomy                        | CPAM 1 | BAC → AC  |
| Kim, 201424     | 1   | 11 yr | M   | Yes     | Asymptomatic                                   | LUL  | Left upper lobectomy                        | CPAM 1 | AC        |

MAC, mucinous adenocarcinoma; CPAM, congenital pulmonary airway malformation; LLL, left lower lobe; BAC, bronchiolo-alveolar carcinoma; RML, right middle lobe; RLL, right lower lobe; AC, adenocarcinoma; LUL, left upper lobe.

*N, number of patients. †Pre-Dx, prenatal diagnosis. ‡Loc, location of pulmonary malformation. §Dx, type of pulmonary malformation. NR, insufficient information.
There was no previously known pathophysiology relating to CPAM or malignant lung tumors, aside from conjecture that the relationship would likely involve abnormal lung tissue development. As exhibited by research on lung cancer morphogenesis in adults, KRAS mutation is associated with epithelial growth factor receptor functions, affecting cell growth, differentiation, and apoptosis. This mutation is especially associated with non–small-cell lung cancers, mainly adenocarcinoma, in adults. Corresponding pediatric research has identified cases in which KRAS mutation was found in patients with mucinous adenocarcinoma associated with CPAM. We therefore concluded that abnormal lung tissue development in neonates due to KRAS mutation is a significant factor associated with CPAM and other malignant lung tumors.

Previous studies indicate that 4%–10% of all lung malignancies that affect children and adolescents are associated with cystic malformations. Studies on associated malignant tumors indicate that CPAM is the most prevalent congenital cystic lung malformation, and adenocarcinoma related to type I CPAM is especially predominant. Previous reports on adenocarcinoma by Casagrande and Pedeviva, Ramos et al., and Kim et al. concluded there was an association with type I CPAM (Table 1). Of 39 reported cases of malignant tumors caused by CPAM in patients aged <18 years, 18 were asymptomatic or only exhibited coughing. Furthermore, 10 of 18 children with adenocarcinoma did not exhibit notable symptoms. While the patient described in this report was surgically treated because of his symptoms, asymptomatic pediatric patients with CPAM should undergo regular radiological monitoring, with consideration of elective surgery if necessary.

To the best of our knowledge, this is the first case report of mucinous adenocarcinoma, associated with KRAS mutation, in a Korean newborn with type II CPAM diagnosed via lung biopsy. This case may provide the foundation for future research on the potential relationships between CPAM and malignant transformation associated with KRAS mutation.

Conflict of interest

We have no relevant financial relationships to disclose or conflicts of interest to report.

References

1. Laberge JM, Flageole H, Pugash D, Khalife S, Blair G, Filiatrault D, et al. Outcome of the prenatally diagnosed congenital cystic adenomatoid lung malformation: a Canadian experience. Fetal Diagn Ther 2001;16:178–86.
2. Baird R, Puligandla PS, Laberge JM. Congenital lung malformations: informing best practice. Semin Pediatr Surg 2014;23:270–7.
3. Ruchonnet-Metrailler I, Leroy-Terquem E, Stirnemann J, Cros P, Ducoin H, Hadchouel A, et al. Neonatal outcomes of prenatally diagnosed congenital pulmonary malformations. Pediatrics 2014;133:e1285–91.
4. Casagrande A, Pedeviva F. Association between congenital lung malformations and lung tumors in children and adults: a systematic review. J Thorac Oncol 2016;11:1837–45.
5. Stocker JT, Madewell JE, Drake RM. Congenital cystic adenomatoid malformation of the lung. Classification and morphologic spectrum. Hum Pathol 1977;8:155–71.
6. MacSweeney F, Papagiannopoulos K, Goldstraw P, Sheppard MN, Corrin B, Nicholson AG. An assessment of the expanded classification of congenital cystic adenomatoid malformations and their relationship to malignant transformation. Am J Surg Pathol 2003;27:1139–46.
7. Riely GJ, Marks J, Pao W. KRAS mutations in non–small cell lung cancer. Proc Am Thorac Soc 2009;6:201–5.
8. Hancock BJ, Di Lorenzo M, Yousef S, Yazbeck S, Marcotte JE, Collin PP. Childhood primary pulmonary neoplasms. J Pediatr Surg 1993;28:1133–6.
9. Ishida M, Igarashi T, Teramoto K, Hanaoka J, Iwai M, Yoshida K, et al. Mucinous bronchioloalveolar carcinoma with K-ras mutation arising in type 1 congenital cystic adenomatoid malformation: a case report with review of the literature. Int J Clin Exp Pathol 2013;6:2597–602.
10. Summers RJ, Shehata BM, Bleacher JC, Stockwell C, Rapkin L. Mucinous adenocarcinoma of the lung in association with congenital pulmonary airway malformation. J Pediatr Surg 2010;45:2256–9.
11. Rossi G, Gasser B, Sartori G, Migaldi M, Costantini M, Mengoli MC, et al. MUC5AC, cytokeratin 20 and HER2 expression and K-RAS mutations within mucinogenic growth in congenital pulmonary airway malformations. Histopathology 2012;60:1133–43.
12. Lantuejoul S, Nicholson AG, Sartori G, Piotot C, Danel C, Brabencova E, et al. Mucinous cells in type I pulmonary congenital cystic adenomatoid malformation as mucinous bronchioloalveolar carcinoma precursors. Am J Surg Pathol 2007;31:961–9.
13. Ramos SG, Barbosa GH, Tavora FR, Jeudy J, Torres LA, Tone LG, et al. Bronchioloalveolar carcinoma arising in a congenital pulmonary airway malformation in a child: case report with an update of this association. J Pediatr Surg 2007;42:E1–4.
14. Kim MY, Kang CH, Park SH. Multifocal synchronous mucinous adenocarcinomas arising in congenital pulmonary airway malformation: a case report with molecular study. Histopathology 2014;65:926–32.
15. Furukawa T, Kimura O, Sakai K, Higashi M, Fumino S, Aoi S, et al. Surgical intervention strategies for pediatric congenital cystic lesions of the lungs: a 20-year single-institution experience. J Pediatr Surg 2015;50:2025–7.
16. Ohye RG, Cohen DM, Caldwell S, Qualman SJ. Pediatric bronchioloalveolar carcinoma: a favorable pediatric malignancy? J Pediatr Surg 1998;33:730–2.
17. Granata C, Gambini C, Balducci T, Toma P, Michelazzi A, Conte M, et al. Bronchioloalveolar carcinoma arising in congenital cystic adenomatoid malformation in a child: a case report and review on malignancies originating in congenital cystic adenomatoid malformation. Pediatr Pulmonol 1998;25:62–6.
18. Papagiannopoulos K, Hughes S, Nicholson AG, Goldstraw P. Cystic lung lesions in the pediatric and adult population: surgical experience at the Brompton Hospital. Ann Thorac Surg 2002;73:1594–8.
19. Stacher E, Ullmann R, Halbwied I, Gogg-Kammerer M, Boccon-Gibod L, Nicholson AG, et al. Atypical goblet cell hyperplasia in congenital cystic adenomatoid malformation as a possible preneoplasia for pulmonary adenocarcinoma in childhood: a genetic analysis. Hum Pathol 2004;35:565–70.
20. Ioachimescu OC, Mehta AC. From cystic pulmonary airway malformation, to bronchioalveolar carcinoma and adenocarcinoma of the lung. Eur Respir J 2005;26:1181-7.
21. Abecasis F, Gomes Ferreira M, Oliveira A, Vaz Velho H. Bronchioalveolar carcinoma associated with congenital pulmonary airway malformation in an asymptomatic adolescent. Rev Port Pneumol 2008;14:285-90.
22. Giubergia V, Barrenechea M, Siminovich M, Pena HG, Murtagh P. Congenital cystic adenomatoid malformation: clinical features, pathological concepts and management in 172 cases. J Pediatr (Rio J) 2012;88:143-8.
23. Li J, Chen GS, Zhang X, Moore L, Cheng H. Congenital cystic adenomatoid malformation with associated mucinous bronchioalveolar carcinoma in a neonate. Fetal Pediatr Pathol 2014;33:29-34.
24. Balkanli S, Ozturk MA, Kose M, Bastug O, Tekelioğlu F, Hasdiraz L, et al. A report of adenocarcinoma in situ and congenital pulmonary airway malformation in a three-day-old infant with a review of the literature. Turk J Pediatr 2014;56:299-302.